Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FlaviPrime: IMOJEV in Flavivirus Naïve and Experienced Participants
NCT03920111Completed
- Sponsor
- University of Liverpool
- Start
- Apr 2021
- Primary completion
- Dec 2021
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Open-label trial of japanese encephalitis chimeric virus vaccine in Japanese encephalitis (JE) (3 arms), sponsored by University of Liverpool. Primary endpoints: Plasmablast Percentage of Total B Cells at 1 week and Neutralisation Titre (50% Viral Plaque Reduction) at 2 months. Started Apr 2021; status: completed.
02
Drugs
japanese encephalitis chimeric virus vaccine
03
Conditions
Japanese encephalitis (JE)
Beyond the preview
Go deeper on NCT03920111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03920111.